Diego Rey

Angel investing

2018

Co-Founder & Chief Scientific Officer

2018 - 2024

Endpoint Health develops therapeutics for immune-mediated diseases including RA, IBD, Vasculitides, as well as Sepsis, and ARDS. Endpoint’s key premise is that biological heterogeneity in these diseases limits efficacy potential and addresses this problem by developing blood-based transcriptomic tests (RNA seq and RT-qPCR) to stratify patients based on immune state to then better align therapy pharmacology to patient biology. Therapeutics in development by Endpoint span first-in-class preclinical through repositioning of approved molecules and include monoclonal antibodies, recombinant proteins, and plasma-derived blood products.

Expert/Part time Partner

2018 - 2021

Visiting Partner

2017 - 2018

Diego was the first Visiting Partner at Y Combinator focused on life sciences and healthcare companies, where he helped founders build their companies developing diagnostics, therapeutics, medical devices, tools, health IT, and industrial biology products. YC has invested in over a thousand founders who have started 5,000+ companies with a combined value of over $600B and that have created tens of thousands of jobs.

Head of Research, GeneWEAVE Division of Roche Molecular Systems

2015 - 2017

Co-Founder & Chief Technology Officer

2010 - 2015

GeneWEAVE developed tests to get the right antibiotic to patients quickly: in vitro diagnostics for the rapid detection and identification of live bacteria directly from patient specimens and phenotypic determination of antibiotic susceptibility. GeneWEAVE was acquired by Roche and the system and first test for MRSA screening received a De Novo Grant from the FDA. Diego invented the core technology and is the author of 27 issued patents covering the product.

Graduate Research Assistant

2004 - 2010

The Batt Lab is led by Liberty Hyde Bailey Professor Dr. Carl A. Batt. Dr. Batt's laboratory strives to provide advancements in basic scientific research that will have a direct impact on society at large. The lab's scientists also work with the community to promote scientific understanding of students of all ages. While at the Batt Lab, I developed strategies for biofunctionalization of carbon nanotubes, quantum dots, and magnetic nanoparticles, and explored their potential as imaging agents and therapeutics. Collaborators of the lab included Ludwig Cancer Research, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital, the Cornell NanoScale Science & Technology Facility, and the Cornell Nanobiotechnology Center. While at Cornell Diego received several fellowships including the National Institutes of Health Fellowship Ruth L. Kirschstein National Research Service Award (2007-2010), the Cornell SAGE Fellowship (2005), the Sloan Fellowship (2004), and the Cornell Nanobiotechnology Center Fellowship (2004).